Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
41. |
ECCT/17/08/09 | A trial to compare two new combinations of antimalarial drugs with the standard combination of antimalarial drugs in Kenyan children An open-label randomised trial to assess the therapeutic efficacy and tolerability of arterolane-piperaquine plus single low dose primaquine versus arterolane-piperaquine plus mefloquine and single low dose primaquine versus artemether-lumefantrine plus single low dose primaquine in the treatment of uncomplicated falciparum malaria in children in Kenya. |
Principal Investigator(s) 1. Philip Bejon Site(s) in Kenya 1. Kilifi County Hospital - Paediatric Out patient and Inpatient department (Kilifi county) 2. Pingilikani Dispensary (Kilifi county) |
04-01-2018 |
View |
42. |
ECCT/18/01/01 | Mal 094 Efficacy, safety and immunogenicity study of GSK Biologicals’ candidate malaria vaccine (SB257049) evaluating schedules with or without fractional doses, early Dose 4 and yearly doses, in children 5-17 months of age. |
Principal Investigator(s) 1. Aaron Samuels 2. Simon Kariuki Site(s) in Kenya 1. Siaya County Referral hospital (Siaya county) 2. Ngiya Health Center (Siaya county) 3. Kogelo Health Center (Siaya county) 4. Tingwangi (Siaya county) 5. Mulaha (Siaya county) 6. Nyathengo (Siaya county) 7. Bal Olengo (Siaya county) |
06-03-2018 |
View |
43. |
ECCT/17/09/04 | A5354 A5354 Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses |
Principal Investigator(s) 1. Brian Baker Site(s) in Kenya KISUMU CRS |
21-03-2018 |
View |
44. |
ECCT/18/04/01 | CKAF156 STUDY A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria. |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. KEMRI CDC (Siaya county) 2. Walter Reed Project (Kisumu county) |
23-08-2018 |
View |
45. |
ECCT/18/07/02 | CONRAD RING Phase IIa, 90-Day Safety, Adherence, and Acceptability Study of Intravaginal Rings Releasing Tenofovir with and without Levonorgestrel among Women in Western Kenya |
Principal Investigator(s) 1. DR. NELLY RWAMBA MUGO Site(s) in Kenya KEMRI CRC |
22-09-2018 |
View |
46. |
ECCT/18/07/07 | A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. GRACE KIRINGA KAGUTHI Site(s) in Kenya 1. Center for Respiratory Diseases Research (Siaya county) 2. KEMRI (Kisumu county) |
04-10-2018 |
View |
47. |
ECCT/18/07/01 | CCNO17 Male contraception study. Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception. |
Principal Investigator(s) 1. Dr John Kinuthia Site(s) in Kenya Couples counselling Center |
19-11-2018 |
View |
48. |
ECCT/18/04/03 | ShangRing vs. Mogen Clamp for EIMC Evaluation of the ShangRing vs. Mogen Clamp for Early Infant Male Circumcision in sub-Saharan Africa |
Principal Investigator(s) 1. Richard Lee 2. Mark Barone Site(s) in Kenya 1. Homa Bay Teaching and Referral Hospital (Homa Bay county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
10-12-2018 |
View |
49. |
ECCT/18/06/04 | RANDOMIZED CONTROLLED TRIAL OF STEPPED UP VITAMIN A SUPPLEMENTATION DOSE ON IMMUNE RESPONSES AMONG INFANTS 6-12 MONTHS AT BUSIA LEVEL 4 HOSPITAL IN BUSIA COUNTY, KENYA BUSIA LEVEL IV HOSPITAL |
Principal Investigator(s) 1. BENARD OCHIENG WESONGA Site(s) in Kenya Busia Level IV Hospital |
29-07-2019 |
View |
50. |
ECCT/19/01/01 | A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Bernhards Ogutu Ragama Site(s) in Kenya 1. Ahero County hospital (Kisumu county) 2. Siaya County Hospital (Siaya county) |
13-08-2019 |
View |